HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Villanueva-Meyer, J. Articles by Marcus, C. S. Search for Related Content PubMed PubMed Citation Articles by Villanueva-Meyer, J. Articles by Marcus, C. S.

Lacrimal Gland Dosimetry for the Brain Imaging Agent Technetium-99m-HMPAO

Division of Nuclear Medicine, Harbor-UCLA Medical Center, Torrance, California

Correspondence: For reprints contact: C.S. Marcus, MD, PhD, Nuclear Medicine Outpatient Clinic, Building A-13, 1000 W.Carson St., Torrance, CA 90509.

ABSTRACT

We calculated lacrimal gland dosimetry for the brain imaging agent ^99mTc-HMPAO. One hundred thirty-eight patients were studied using a dedicated brain imaging device. Only 11% of the patients showed lacrimal gland uptake. For a 740-MBq (20 mCi) injected dose of ^99mTc-HMPAO, the radiation exposure to the lacrimal glands is 10.2 mGy (1.02 rad), or 0.0138 mGy/MBq (0.051 rad/mCi). These values are five times lower than the ones reported by the manufacturer of HMPAO. As the dosimetry calculation only for subjects showing ^99mTc-HMPAO uptake in the lacrimal gland, the average radiation dose to all subjects is considerably lower, 1/10 of the estimated value.